Last reviewed · How we verify
Ethynyl-estradiol plus cyproterone acetate — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Ethynyl-estradiol plus cyproterone acetate (Ethynyl-estradiol plus cyproterone acetate) — Hospital Universitario Ramon y Cajal.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ethynyl-estradiol plus cyproterone acetate TARGET | Ethynyl-estradiol plus cyproterone acetate | Hospital Universitario Ramon y Cajal | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ethynyl-estradiol plus cyproterone acetate CI watch — RSS
- Ethynyl-estradiol plus cyproterone acetate CI watch — Atom
- Ethynyl-estradiol plus cyproterone acetate CI watch — JSON
- Ethynyl-estradiol plus cyproterone acetate alone — RSS
Cite this brief
Drug Landscape (2026). Ethynyl-estradiol plus cyproterone acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/ethynyl-estradiol-plus-cyproterone-acetate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab